bluebird bio received two additional notification letters from Nasdaq on August 20, 2024, citing non-compliance with listing rules due to delayed Q1 and Q2 2024 quarterly reports. These notices follow an earlier notification regarding the delayed 2023 annual report, which requires restatement of financial statements for 2022 and the first three quarters of 2023.The company has until October 14, 2024, to regain compliance by filing all delayed reports, including the 2023 Form 10-K and both quarterly reports. Nasdaq requires an updated compliance plan by September 4, 2024. The notices have no immediate impact on the company's stock listing on Nasdaq.The delay stems from the company's March 26 announcement to restate its consolidated financial statements for 2022 and quarterly reports for 2022-2023. bluebird bio is working to complete these filings expeditiously while maintaining its commercial operations in gene therapy development.

bluebird bio received two additional notification letters from Nasdaq on August 20, 2024, citing non-compliance with listing rules due to delayed Q1 and Q2 2024 quarterly reports. These notices follow an earlier notification regarding the delayed 2023 annual report, which requires restatement of financial statements for 2022 and the first three quarters of 2023.The company has until October 14, 2024, to regain compliance by filing all delayed reports, including the 2023 Form 10-K and both quarterly reports. Nasdaq requires an updated compliance plan by September 4, 2024. The notices have no immediate impact on the company's stock listing on Nasdaq.The delay stems from the company's March 26 announcement to restate its consolidated financial statements for 2022 and quarterly reports for 2022-2023. bluebird bio is working to complete these filings expeditiously while maintaining its commercial operations in gene therapy development.